Aarkstore - The Chinese Pharmaceuticals Market to 2024

Aarkstore - The Chinese Pharmaceuticals Market to 2024

Aarkstore - The Chinese Pharmaceuticals Market to 2024


The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access – and this is only the OTC market – what has the growth been throughout the whole Chinese pharma sector? This report will tell you.

“China’s pharmaceutical” sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably. Have you captured enough of the Chinese market?

Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world’s diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types – your company must capture a segment of this market TODAY.

Anti-Counterfeiting and anti-corruption – How the Chinese market is changing

Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese...

Similar Essays